Group 1 - The pharmaceutical e-commerce sector saw a rise of 2.00%, ranking 8th among concept sectors, with 124 stocks increasing in value [1] - Notable gainers included Rundu Co., Aosaikang, and Wanbangde, which reached their daily limit up, while Furuishi and Laimei Pharmaceuticals also performed well with increases of 9.55%, 8.48%, and 5.54% respectively [1] - The sector experienced a net inflow of 750 million yuan from main funds, with 83 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Rundu Co. led the net inflow with 145 million yuan, followed by Yipin Hong, Furuishi, and Zhongsheng Pharmaceuticals with net inflows of 98.68 million yuan, 83.98 million yuan, and 70.42 million yuan respectively [2] - In terms of net inflow ratio, Rundu Co. had a leading rate of 42.20%, followed by Zhejiang Zhenyuan and ST Huluwawa at 29.25% and 16.55% respectively [3] Group 3 - The pharmaceutical e-commerce concept had a total of 124 stocks rising, with significant contributions from stocks like Rundu Co. and Aosaikang, which both showed strong performance [1][2] - The overall market sentiment in the pharmaceutical e-commerce sector appears positive, as indicated by the substantial net inflows and the number of stocks experiencing gains [2][3]

Group 1 - The hepatitis concept sector rose by 2.17%, ranking 7th among concept sectors, with 120 stocks increasing in value, including notable gainers such as Rundu Co., Wanbangde, and Lisheng Pharmaceutical, which hit the daily limit [1][2] - The top gainers in the hepatitis concept sector included Guangshantang, Furuishi, and Laimei Pharmaceutical, with increases of 16.55%, 9.55%, and 8.48% respectively [1][2] - The sector experienced a net inflow of 1.831 billion yuan, with 87 stocks receiving net inflows, and 16 stocks exceeding 50 million yuan in net inflow, led by Qianhong Pharmaceutical with a net inflow of 227 million yuan [2][3] Group 2 - The leading stocks by net inflow ratio included Rundu Co. at 42.20%, ST Weiming at 33.93%, and Zhejiang Zhenyuan at 29.25% [3] - The top stocks in the hepatitis concept sector based on net inflow included Qianhong Pharmaceutical, ST Weiming, and Hanyu Pharmaceutical, with respective net inflows of 226.89 million yuan, 168.20 million yuan, and 165.89 million yuan [3][4] - The overall performance of the hepatitis concept sector reflects strong investor interest and significant capital inflows, indicating potential growth opportunities within the sector [2][3]

Market Overview - The Shanghai Composite Index is at 3500.42 points, slightly down by 0.13%, with a total trading volume of 674.96 billion yuan [1] - As of now, 50 A-shares have surpassed their annual line, indicating a positive market sentiment [1] Notable Stocks - The stocks with the highest deviation rates above the annual line include: - Furui Co., Ltd. (300049) with a deviation rate of 5.83% and a daily increase of 7.83% [1] - Haide Co., Ltd. (000567) with a deviation rate of 4.84% and a daily increase of 7.77% [1] - Tianye Co., Ltd. (832023) with a deviation rate of 3.71% and a daily increase of 6.35% [1] - Other stocks that have just crossed the annual line with smaller deviation rates include: - Wansheng Co., Ltd. (002739) with a deviation rate of 2.70% and a daily increase of 3.02% [1] - ST Guandian (688287) with a deviation rate of 2.14% and a daily increase of 2.67% [1] Trading Activity - The trading turnover rate for notable stocks varies, with Furui Co., Ltd. at 4.06% and Haide Co., Ltd. at 2.59% [1] - The latest prices for these stocks are as follows: - Furui Co., Ltd. at 39.40 yuan [1] - Haide Co., Ltd. at 6.52 yuan [1] - Tianye Co., Ltd. at 4.69 yuan [1]

[Inner Mongolia Furui Medical Technology Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E5%86%85%E8%92%99%E5%8F%A4%E7%A6%8F%E7%91%9E%E5%8C%BB%E7%96%97%E7%A7%91%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%202025%20%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) This report provides a preliminary forecast for the company's performance in the first half of 2025, highlighting key financial indicators and factors influencing changes [Key Performance Indicators Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a trend of "rising revenue, declining profit" for the first half of 2025, with net profit attributable to shareholders expected to decrease by 20% to 34% 2025 H1 Performance Forecast | Item | Current Period (2025 H1) | Prior Period (2024 H1) | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Profit: 50.00 million CNY - 60.00 million CNY | Profit: 75.36 million CNY | | YoY Change | Decrease: 34% - 20% | - | | **Net Profit After Non-Recurring Items** | Profit: 51.50 million CNY - 61.50 million CNY | Profit: 74.46 million CNY | | YoY Change | Decrease: 31% - 17% | - | [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The decline in net profit is primarily due to non-operating factors, including a significant increase in equity incentive expenses and foreign exchange losses, despite steady growth in core businesses - Excluding the impact of equity incentive expenses and foreign exchange gains/losses, net profit attributable to shareholders for the reporting period is estimated to be **75.00-85.00 million CNY**, representing a year-over-year increase of approximately **5%-19%**, reflecting healthy growth in core operations[6](index=6&type=chunk) [Core Business Performance](index=1&type=section&id=3.1%20%E6%A0%B8%E5%BF%83%E4%B8%9A%E5%8A%A1%E8%A1%A8%E7%8E%B0) During the reporting period, the company's core businesses maintained growth, with medical device business serving as the primary growth engine, while pharmaceutical and medical services businesses also developed steadily Performance by Business Segment | Business Segment | Estimated Operating Revenue (million CNY) | YoY Growth | Estimated Net Profit (million CNY) | | :--- | :--- | :--- | :--- | | Medical Devices | 470 - 490 | 11% - 16% | 73 - 78 | | Pharmaceuticals and Medical Services | 225 - 240 | 3% - 10% | 35 - 40 | [Impact of Non-Operating Factors](index=1&type=section&id=3.2%20%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E5%9B%A0%E7%B4%A0%E5%BD%B1%E5%93%8D) The decline in net profit is primarily attributed to a significant year-over-year increase in equity incentive share-based payment expenses and foreign exchange losses due to currency depreciation Comparison of Major Non-Recurring Items | Impact Item | Current Period (2025 H1) | Prior Period (2024 H1) | | :--- | :--- | :--- | | Equity Incentive Expenses | Approx. 12.44 million CNY | 5.18 million CNY | | Foreign Exchange Gains/Losses | Loss approx. 15.24 million CNY | Gain 8.57 million CNY | [Important Disclosures and Risk Warnings](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company clarifies that this performance forecast is based on preliminary calculations and has not been audited, advising investors to exercise caution due to inherent investment risks - This performance forecast is a preliminary estimate by the company's finance department and has not been audited[4](index=4&type=chunk) - Non-recurring gains and losses are expected to have an impact of approximately **1.50 million CNY** on net profit for the first half of 2025[7](index=7&type=chunk) - The company advises that final specific data will be detailed in the 2025 semi-annual report, urging investors to make cautious decisions and be aware of investment risks[7](index=7&type=chunk)

7月14日，福瑞股份今日收盘37.17元，下跌2.00%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到99.80倍，总市值99.00亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.90倍，行业中值37.22倍，福瑞股份排 名第105位。 资金流向方面，7月14日，福瑞股份主力资金净流出4606.27万元，近5日总体呈流出状态，5日共流出 4805.47万元。 内蒙古福瑞医疗科技股份有限公司的主营业务是肝病领域的药品生产与销售、诊断设备研发与销售以及 医疗服务相关业务。公司的主要产品是复方鳖甲软肝片。 最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13福瑞股份99.8087.395.5699.00亿行业平均 51.9049.564.52107.49亿行业中值37.2237.602.5051.67亿1九安医疗10.4010.510.82175.44亿2英科医疗 11.0611.930.98174.77亿3新华医疗14 ...

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [4][35]. Core Insights - The MASH drug market is projected to exceed $32.2 billion by 2030, driven by the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MAFLD) and its progression to MASH [1][16]. - The approval of the first MASH drug, Resmetirom, by the FDA in March 2024 marks a significant milestone, leading to increased interest and investment from major pharmaceutical companies [2][17]. - The demand for diagnostic equipment, particularly non-invasive tests like VCTE, is expected to surge as new MASH drugs are approved globally, enhancing the need for effective screening and clinical assessment tools [2][21]. Financial Summary - Revenue is projected to grow from 1,154 million yuan in 2023 to 3,629 million yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 47.7% [1][28]. - Net profit attributable to the parent company is expected to increase from 102 million yuan in 2023 to 462 million yuan in 2027, with a significant growth rate of 59.4% in 2027 [1][28]. - The company's return on equity (ROE) is forecasted to rise from 9.6% in 2023 to 21.1% in 2027, indicating improving profitability and efficiency [1][28]. Product and Market Position - The company's flagship product, the FibroScan series, is the first non-invasive diagnostic device to quantify liver stiffness using transient elastography, receiving multiple global certifications [3][23]. - FibroScan has been included in various liver disease detection guidelines by leading health organizations, enhancing its credibility and market presence [3][23]. - The company employs multiple business models for its FibroScan products, including one-time sales, per-use fees, and leasing, allowing for flexibility in market penetration [24][25]. Future Growth Potential - The report anticipates that the company will achieve net profits of 188 million yuan, 290 million yuan, and 462 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 53.4, 34.6, and 21.6 [8][26]. - The strategic collaborations with leading pharmaceutical companies are expected to enhance the company's market position and drive revenue growth [3][23].

Group 1: Company Performance and Goals - The company is confident in achieving its annual target of installing 4,000 units by the end of 2025 [1] - In the first half of 2025, the company plans to install 2,400 units, which is an increase of nearly 5 times compared to the previous year [5] - As of July 10, 2025, the number of shareholders is 20,833 [5] Group 2: Product and Market Insights - FibroScan devices are recognized by multiple authoritative organizations, including WHO and EASL, as a standard for liver disease detection [3] - The global market size for varicose vein ultrasound treatment devices is estimated to be approximately $1.06 billion in 2024 [6] - The company’s device, FibroScan, has a cost of about €10,000 per unit, requiring 250 tests to break even [1] Group 3: Financial and Operational Strategies - The company has conducted special studies to mitigate the impact of currency fluctuations on financial reports [2] - Revenue from the device business, including per-use charges and leasing, amounted to 412 million yuan, accounting for 44.62% of total revenue [7] - The company has transitioned all dollar-denominated funds into euros to minimize exchange rate impacts [6] Group 4: Collaborations and Partnerships - The company collaborates with domestic MASH drug research enterprises for the FibroScan series devices [1] - Echosens, a partner in Europe, operates under a mixed model of direct sales and distribution in certain countries [2] - The company is actively pursuing strategic partnerships to enhance its market presence and product offerings [4]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与投资者的互动交流，内蒙古福瑞医疗科技股份有限公司（以下简称 "公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络有限公司联 合举办的"内蒙古辖区上市公司 2025 年投资者网上集体接待日活动"，现将相关事项 公告如下： 本次活动将采用网络远程的方式举行，投资者可登录" 全景路演" 网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次 互动交流，活动时间为 2025 年 7 月 11 日（周五）16:00-18:00。届时公司高管将在线就 公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 证券代码：300049 证券简称：福瑞股份 公告编号：2025-027 内蒙古福瑞医疗科技股份有限公司 关于参加内蒙古辖区上市公司 2025 年投资者 网上集体接待日活动的公告 二零二五年七月九日 特此公告。 内蒙古福瑞医疗科技股份有限公司董事 ...

Core Viewpoint - The article highlights the dual mechanism of action of Furuishi's core product, Compound Turtle Shell Soft Liver Tablets, in treating intrahepatic cholangiocarcinoma, emphasizing its direct and indirect anti-tumor effects [3][5]. Company Overview - Furuishi Co., established in 1998 and listed in 2010, focuses on the diagnosis and treatment of liver diseases, with its main product being Compound Turtle Shell Soft Liver Tablets, the first approved traditional Chinese medicine for liver fibrosis treatment [6][8]. - The company reported a total revenue of 1.349 billion yuan in 2024, a year-on-year increase of 16.93%, with over 60% of its revenue coming from overseas markets [9]. Product Performance - Compound Turtle Shell Soft Liver Tablets have been validated over 20 years in the market, becoming the leading brand for anti-liver fibrosis medications [8]. - In 2021, the sales of Compound Turtle Shell Soft Liver Tablets in public hospitals were approximately 230.62 million yuan, maintaining its position as the top-selling product in its category, although the competitive landscape is tightening [10][11]. Financial Analysis - The pharmaceutical segment contributed about 30% to the company's revenue, while equipment and technology accounted for approximately 70% [9][12]. - The overall gross margin for the pharmaceutical business is around 50%, with proprietary drug margins higher at about 60%, indicating growth challenges in the pharmaceutical sector [15]. Market Potential - The annual incidence of intrahepatic cholangiocarcinoma in China is estimated at 40,000 to 60,000 cases, with treatment costs around 300,000 yuan, presenting a significant market opportunity for the company's products [17]. Medical Device Segment - Furuishi's main medical devices include the FibroScan series, which is recognized globally for non-invasive liver fibrosis diagnosis, with a compound annual growth rate of 18% since 2015 [20][23]. - The device segment generated 832 million yuan in revenue in 2023, a 35% increase, and is projected to reach 918 million yuan in 2024, reflecting strong growth driven by innovative sales models [24][25]. Innovation and R&D - The company has historically relied on acquired products, with limited internal R&D for new drugs or devices, maintaining R&D expenditure at around 10% of revenue [40][44]. - Recent innovations include a pay-per-use model for devices, which has significantly boosted revenue growth [26][48]. Future Outlook - The company is exploring opportunities in the weight loss drug market, leveraging its FibroScan technology for ongoing liver monitoring in clinical trials [28][29]. - Furuishi plans to expand its healthcare services by acquiring a majority stake in a hospital management company, indicating a strategic shift towards integrated healthcare solutions [48][50].